Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia

Pharmacogenomics Journal

Volumn 12, Issue 5, 2012, Pages 379-385

  Salazar, J ^a,b   Altes A ^c   Del Rio E ^a,b   Estella, J ^d   Rives, S ^d   Tasso, M ^e   Navajas, A ^f   Molina, J ^g   Villa, M ^h   Vivanco, J L ⁱ   Torrent, M ^a   Baiget, M ^b   Badell, I ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c Althaia   (Spain)

^d HOSPITAL SANT JOAN DE DÉU   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g Universidad Pública de Navarra   (Spain)

^h Hospital Universitario Madrid Montepríncipe   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

childhood acute lymphablastic leukaemia; methotrexate; pharmacogenetic

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLCYSTEINE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DHFR GENE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG METABOLISM; EVENT FREE SURVIVAL; FEMALE; GENE; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RFC1 GENE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84866740024     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.25     Document Type: Article

References (28)

1. Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr Opin Pediatr 2007; 19: 15-22.
2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
3. Jeha S, Pui CH. Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 973-990.
4. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117-129.
5. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832-3834.
6. Dulucq S, St-Onge G, Gagne V, Ansari M, Sinnett D, Labuda D et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood 2008; 111: 3692-3700.
7. Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P et al. DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res 2009; 15: 6931-6938.
8. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 50-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-197.
9. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001; 7: 4096-4101.
10. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ et al. A novel single nucleotide polymorphism within the 50 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-2904.
11. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359: 1033-1034.
12. Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 2005; 5: 374-380.
13. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335: 1041-1048.
14. Costea I, Moghrabi A, Krajinovic M. The influence of cyclin D1 (CCND1) 870A4G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 2003; 13: 577-580.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
16. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
17. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009; 146: 489-503.
18. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
19. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-6007.
20. Marcuello E, Altes A, Menoyo A, Rio ED, Baiget M. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 2006; 57: 835-840.
21. Badell I, Munoz A, Estella J, Fernandez-Delgado R, Javier G, Verdeguer A et al. Long-term results of two consecutive trials in childhood acute lymphoblastic leukaemia performed by the Spanish Cooperative Group for Childhood Acute Lymphoblastic Leukemia Group (SHOP) from 1989 to 1998. Clin Transl Oncol 2008; 10: 117-124.
22. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4: 66-72.
23. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482-2487.
24. Pietrzyk JJ, Bik-Multanowski M, Balwierz W, Skoczen S, Wojcik D, Chybicka A et al. Additional genetic risk factor for death in children with acute lymphoblastic leukemia: a common polymorphism of the MTHFR gene. Pediatr Blood Cancer 2009; 52: 364-368.
25. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf 2008; 7: 147-158.
26. Turello R, Rentsch K, Di Paolo E, Popovic MB. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism. Pediatr Blood Cancer 2008; 50: 154-156.
27. Gammon DC, Bhatt MS, Patel B, Anderson M, Van Horn A, Glantz MJ. Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism. J Oncol Pharm Pract 2008; 14: 153-156.
28. Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 912-917.